- Home
- PRAX vs ABVX Comparison
PRAX vs ABVX Comparison
Compare PRAX & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRAX | ABVX |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 9.2B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRAX | ABVX |
|---|---|---|
| Price | $312.37 | $119.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $397.85 | $130.09 |
| AVG Volume (30 Days) | 623.7K | ★ 2.1M |
| Earning Date | 02-27-2026 | 08-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,463,000.00 | $6,231,374.00 |
| Revenue This Year | N/A | $6.80 |
| Revenue Next Year | $14,827.76 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 364.98 | N/A |
| 52 Week Low | $26.70 | $4.77 |
| 52 Week High | $326.91 | $148.83 |
Technical Indicators
Market Signals| Indicator | PRAX | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 63.20 | 47.95 |
| Support Level | $266.93 | $113.64 |
| Resistance Level | $326.91 | $122.50 |
| Average True Range (ATR) | 17.87 | 8.73 |
| MACD | 0.13 | -1.40 |
| Stochastic Oscillator | 75.94 | 36.25 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.